Skip to the story

Vol. I · No. 1

Morning ColumnThe letter

Current News · Sourced report

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk

FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate no

News Desk · Nov 9, 2026 · U.S. Food and Drug Administration

Open the source

This item is a public release from the U.S. Food and Drug Administration. The source date is Nov 9, 2026. The next paragraph is the agency's own short text. Morning Column did not rewrite it.

FDA today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

The full release is on the source page. This page is not personal medical advice.

This page is general information from the sources below. It is not personal medical advice, a diagnosis, or a treatment plan. Talk with a qualified clinician about your own health. Read the disclaimer.

References

  1. U.S. Food and Drug Administration. FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk. Nov 9, 2026.

See a factual error? Write to contact@morningcolumn.com. The corrections log is public.